FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer By Ogkologos - January 29, 2026 165 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRITON3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Cancer in children and young people: how far we’ve come September 29, 2021 EMA Recommends Granting a Marketing Authorisation for Aumolertinib January 8, 2026 Coping With the Holidays During COVID-19 and Cancer November 24, 2020 Professor Eithne Costello: On the road to early detection November 12, 2021 Load more HOT NEWS Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and... Picking out the sound of tumours Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... Mortality Trends for Most Cancers Remain Favourable In the EU, Although...
